Nicholas Salgia

Nicholas Salgia.

Nicholas Salgia

Nicholas Salgia

Thesis Title

Unraveling and applying the paradoxical immune sensitivity of sarcomatoid renal cell carcinoma

Research Publications Overview

Publications

  • Bergerot CD, Philip EJ, Malhotra J, Bergerot PG, Castro DV, Govindarajan A, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin ZB, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Racial and ethnic differences in perceptions of germline or somatic DNA sequencing among patients with advanced prostate, urothelial, or kidney cancer. Journal of Genetic Counseling. 2023 Sep;00:1-5. doi:10.1002/jgc4.1786
  • Bergerot CD, Philip EJ, Govindarajan A, Castro D, Malhotra J, Bergerot P, Salgia S, Salgia M, Salgia N, Hsu J, Meza L, Zengin ZB, Liu S, Chehrazi-Raffle A, Tripathi A, Dorff T, Pal S. Changes in Perception of Cure Among Patients With Genitourinary Cancers Initiating Immune Checkpoint Inhibitors: A Longitudinal Study. Clin Genitourin Cancer. 2023 Jun 2:S1558-7673(23)00136-2. doi: 10.1016/j.clgc.2023.05.018. Epub ahead of print.
  • Meza L, Zengin Z, Salgia S, Malhotra J, Karczewska E, Dorff T, Tripathi A, Ely J, Kelley E, Mead H, Hsu J, Dizman N, Salgia N, Chawla N, Chehrazi-Raffle A, Muddasani R, Govindarajan A, Roc A, Liu S, Salgia R, Trent J, Altin J, Pal SK. Twelve-Month Follow-up of the Immune Response After COVID-19 Vaccination in Patients with Genitourinary Cancers: A Prospective Cohort Analysis. The Oncologist. 2023 Mar. Epub ahead of print. doi: 10.1093/oncolo/oyad067.
  • Zengin Z*, Govindarajan A*, Salgia N*, Sayegh N, Tripathi N, Muddasani R, Chehrazi-Raffle A, Feng M, Mercer BD, Ladbuy C, Hao C, Salgia S, Chawla N, Meza L, Malhotra J, Dizman N, Hsu J, Castro D, Chang M, Zhang J, Byron S, Lyou Y, Dorff T, Pal SK, Dandapani S. Genomic and transcriptomic predictors of response from stereotactic body radiation therpay in patients with metastatic renal cell carcinoma. European Urology Oncology. 2023 Jan; [*Co-first authors]
  • Dizman N, Meza L, Bergerot P, Alcantara M, Dorff T, Lyou Y, Frankel P, Cui Y, Mira V, Llamas M, Hsu J, Zengin Z, Salgia N, Salgia S, Malhotra J, Chawla N, Chehrazi-Raffle A, Muddasani R, Gillece J, Reining L, Trent J, Takahashi M, Oka K, Higashi S, Kortylewski M, Highlander SK, Pal SK. Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine. 2022 Apr;28(4):704-712. doi: 10.1038/s41591-022-01694-6. Epub 2022 Feb 28. PMID: 35228755; PMCID: PMC9018425. 
  • Malhotra J, Meza L, Salgia N, Pal SK. Predictive Biomarkers of Immunotherapy Efficacy in RCC and Their Role in Non-metastatic Stages. In: Necchi A, Spiess PE (eds) Neoadjuvant Immunotherapy Treatment of Localized Genitourinary Cancers (1), 221-227. New York, New York: Springer. 2022 Jan. doi:10.1007/978-3-030-80546-3_17
  • Chehrazi-Raffle A, Meza L, Alcantara M, Dizman N, Bergerot P, Salgia N, Hsu J, Ruel N, Salgia S, Malhotra J, Karczewska E, Kortylewski M, Pal SK. Circulating cytokines associated with clinical response to systemic therapy in metastatic renal cell carcinoma. Journal of Immunotherapy for Cancer. 2021 Mar;9(3):e002009. doi:10.1136/jitch-2020-002009. 
  • Zengin ZB, Weipert CM, Salgia N, Dizman N, Hsu J, Meza L, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Chawla N, Philip EJ, Kiedrowski LA, Maughan BL, Rathi N, Goel D, Chouieri TK, Agarwal N, Pal SK. Complementary role of circulating tumor DNA assessment and tissue genomic profiling in metastatic renal cell carcinoma. Clinical Cancer Research. 2021 Jun;Epub ahead of print. doi:10.1158/1078-0432.CCR-21-0572. 
  • Salgia NJ, Govindarajan A, Pal SK. Second-line nivolumab for patients with metastatic renal cell carcinoma in India: A call for expanding global access to clinical trials. Cancer Research Statistics and Treatment. 2021 Jun;4(2):401-402. doi:10.4103/crst.crst_78_21. 
  • Salgia S, Salgia N, Prajapati S, Seghal I, Bautista F, Ruel N, Salgia M, Salgia DA, Salgia R, Pal SK. Twitter as a tool to spread communication regarding genitourinary cancers during the COVID-19 pandemic. Kidney Cancer. 2021 Jun;5(2):73-78. doi:10.3233/KCA-210115.
  • Meza L, Salgia NJ, Patel KC, Pal SK. Learning from BISCAY: the future of biomarker-based trial design in bladder cancer. Cancer Cell. 2021 July12;39(7):910:912. doi:10.1016/j.ccell.2021.06.011. 
  • Salgia NJ*, Chehrazi-Raffle A*, Hsu J, Zengin Z, Salgia S, Chawla NS, Meza L, Malhotra J, Dizman N, Muddasani R, Ruel N, Cianfrocca M, Gong J, Anand S, Chiu V, Yeh J, Pal SK. Characterizing the relationships between tertiary and community cancer providers: Results from a survey of medical oncologists in Southern California. Cancer Medicine. 2021 Aug;10(16):5671-5680. doi: 10.1002/cam4.4119.
  • Stack ME, Salgia N, Vigneswaran WT. (2015) Successful primary repair of a colopericardial fistula: a Late complication of esophageal replacement. Annals of Thoracic Surgery, 100(4):1459-1461. doi:10.1016/j.athoracsur.2014.12.046. 
  • Salgia NJ, Pal SK. (2019). Editorial Comment. Journal of Urology, 201(3):548. doi:10.1097/01.JU.0000553713.64297.bb. 
  • Salgia NJ, Dara Y, Bergerot P, Salgia M, Pal SK. (2019). The changing landscape of management of metastatic renal cell carcinoma: current treatment options and future directions. Current Treatment Options in Oncology, 20(5):41. doi:10.1007/s11864-019-0638-1. 
  • Dara YE, Salgia NJ, Pal SK. (2020). Renal Cell Carcinoma. Oncology in the Precision Medicine Era (1):123-134. New York, New York: Springer. doi:10.1007/978-3-030-31471-2 
  • Salgia NJ, Feng M, Prajapati D, Harwood R, Dara Y, Ruel N, Salgia M, Pal SK. (2020). Examining the association of academic rank and productivity with metrics of Twitter utilization amongst kidney cancer specialists. Kidney Cancer, 4(2):103-109. Doi:10.3233/KCA-200083. 
  • Meng WS, Salgia NJ, Pham NB, Velanker KY, Pal SK. (2020). A drug delivery perspective on intratumoral-immunotherapy in renal cell carcinoma. Urologic Oncology, S1078-1439(20)30105-8. Published Online Ahead of Print. doi:10.116/j.urolonc.2020.03.108. 
  • Salgia NJ, Philip EJ, Ziari M, Yap K, Pal SK. (2020). Advancing the science and management of renal cell carcinoma: bridging the divide between academic and community practices. Journal of Clinical Medicine, 9(5):1508. doi:10.3390/jem9051508. 
  • Salgia NJ, Zengin ZB, Pal SK. (2020). Tivozanib in renal cell carcinoma: a new approach to previously treated disease. Therapeutic Advances in Medical Oncology. doi:10.1177/1758835920923818. 
  • Dizman N, Lyou Y, Salgia NJ, Bergerot PG, Hsu J, Trent J, Byron S, Pal SK. (2020). Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic sequencing analysis. Journal of Immunotherapy for Cancer, 8(2):e000953. doi:10.1136/jitc-2020-000953. 
  • Salgia NJ, Bergerot PG, Maia MC, Dizman N, Hsu J, Gillece JD, Folkerts M, Reining L, Trent J, Highlander SK, Pal SK. (2020). Stool microbiome profiling of patients with metastatic renal cell carcinoma receiving anti-PD-1 immune checkpoint inhibitors. European Urology. S0302-2838(20)30543-1. Published Online Ahead of Print. doi:10.1016/j.eururo.2020.07.011. 
  • Bergerot CD, Philip EJ, Bergerot PG, Hsu J, Dizman N, Salgia M, Salgia N, Vaishampayan U, Battle D, Loscalzo M, Dale W, Pal SK. Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer. 2021 Feb 1;127(3):354-358. doi: 10.1002/cncr.33238.
  • Dizman N*, Salgia NJ*, Bergerot PG, Hsu J, Pal SK. Race/Ethnicity and Survival in Metastatic Renal Cell Carcinoma: Outcomes for Patients Receiving First Line Targeted Therapies. Kidney Cancer. 2020;4(3):159-166. doi:10.3233/KCA-200092.
  • Zengin ZB, Salgia NJ, Cherazi-Raffle A, Meza L, Malhotra J, Pal SK. (2020). Immune related adverse events: classification and management appraoches in advanced kidney cancer. The Cancer Journal. In Press. 
  • Hansen B, Zhao J, Helfrich K, Li N, Iancau V, Zolotarev A, Zakharkin S, Kalyanasundaram A, Subr M, Dastagir N, Sharma R, Artiga E, Salgia N, Houmsse M, Kahaly O, Janssen P, Mohler P, Mokadam N, Whitson B, Afzal M, Simonetti O, Hummel J, Fedorov V. Unmasking arrhythmogenic hubs of reentry driving persistent atrial fibrillation for patient-specific treatment. Journal of the American Heart Association. 2020;9(19):e017789. doi:10.1161/JAHA.120.017789.

Professional/Educational Meetings/Abstracts

  • Salgia NJ, Aubrecht W, Wang L, Ram B, Long M, Eng K, Xu B, Kaffman E, Muhitch J (2023, Jul 14). Stratifying patients based on abundance of sarcomatoid features reveals differential transcriptomes and survival outcomes in sarcomatoid renal cell carcinoma. Poster presented at the 2023 Kidney Cancer Research Symposium.
  • Salgia NJ, Chow J, Long M, Eng K, Aubrecht W, Daza J, Xu B, Bshara W, Kaffman E, Muhitch J (2023, June 16). Modeling the initiation and immunogenicity of sarcomatoid dedifferentiation in renal cell carcinoma. Oral abstract presented at the 2023 Roswell Park Comprehensive Cancer Center Immunology Retreat.
  • Salgia NJ, Chow J, Long M, Eng K, Aubrecht W, Daza J, Xu B, Bshara W, Kaffman E, Muhitch J (2023, Feb 22). Modeling the initiation and immunogenicity of sarcomatoid dedifferentiation in renal cell carcinoma. Oral abstract presented at the 2023 Translational Cancer Centers Consortium Annual Meeting.
  • Zengin ZB, Govindarajan A, Muddasani R, Salgia N, Sayegh N, Tripathi N, Salgia S, Meza LA, Zhang J, Chawla NS, Chehrazi-Raffle A, Malhotra J, Dizman N, Hsu J, Castro DV, Byron SA, Dandapani SV, Pal SK. (2022, June 2). Transcriptomic profiling identifies genomic markers associated with benefit from stereotactic body radiation therapy (SBRT) in oligoprogressive metastatic renal cell carcinoma (mRCC). Poster presented by Z Zengin at the 2022 ASCO Annual Meeting.
  • Chehrazi-Raffle A, Meza LA, Alcantara M, Salgia N, Dizman N, Bergerot PG, Hsu J, Kortylewski M, Pal SK. (2021, February 13). Distinct cytokines predict response to immunotherapy and targeted therapy in metastatic renal cell carcinoma (mRCC). Poster presented by A Chehrazi-Raffle at the 2021 ASCO GU Sympsoium. 
  • Zengin ZB, Weipert C, Hsu J, Salgia N, Hensel C, Maughan BL, Rathi N, Goel D, Agarwal N, Choueiri T, Pal SK. (2021, February 13). Illustration of temporal evolution in patients with metastatic renal cell carcinoma (mRCC) using both circulating tumor DNA (ctDNA) and tissue-based genomic data. Oral abstract presented by Z Zengin at the 2021 ASCO GU Symposium. 
  • Salgia NJ, Zengin Z, Dizman N, Hsu J, Meza L, Chawla NS, Chehrazi-Raffle A, Muddasani R, Salgia S, Malhotra J, Pal SK, Dandapani S. (2021, April 23). Stereotactic body radiation therapy (SBRT) for prolongation of systemic therapy in oligoprogressive metastatic renal cell carcinoma (mRCC). Poster presented by N Salgia at the 2021 European International Kidney Cancer Symposium (EIKCS). 
  • Malhotra J, Weipert C, Hsu J, Salgia NJ, Hensel C, Maughan BJ, Rathi N, Goel D, Agarwal N, Choueiri T, Pal SK, Zengin ZB. (2021, April 23). Feasibility of cell-free circulating tumor DNA (ctDNA) in metastatic renal cell carcinoma (mRCC) and impact of temporal heterogeneity on agreement with tissue-based molecular testing using a multi-institutional cohort. Poster presented by J Malhotra at the 2021 EIKCS. 
  • Salgia S, Dizman N, Bergerot PG, Karimi M, Hsu J, Gillece J, Folkerts M, Reining LJ, Trent JM, Highlander S, Bergerot C, Salgia N, Zengin Z, Meza L, Malhotar J, Mudassani R, Chawla N, Govindarajan A, Pal SK, Chehrazi-Raffle A. (2021, April 23). Plasma cytokine concentrations are associated with gut microbial composition in metastatic renal cell carcinoma (mRCC). Poster presented by S Salgia at the 2021 EIKCS. 
  • Bergerot PG, Bergerot CD, Philip EJ, Salgia M, Salgia N, Hsu J, Dizman N, Pal SK. (2021, May 22). Perception of immunotherapy among patients with metastatic renal cell carcinoma. Poster presented by PG Bergerot at the 2021 International Psycho-Oncology Society World Conference. 
  • Meza LA, Dizman N, Bergerot PG, Dorff TB, Lyou Y, Frankel PL, Mira V, Llamas M, Hsu J, Zengin ZB, Salgia N, Salgia S, Malhotra J, Chawla NS, Chehrazi-Raffle A, Gillece JD, Reining LJ, Trent JM, Highnalder SK, Pal SK. (2021, June 4). First results of a randomized phase Ib study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma. Poster presented by L Meza at the 2021 ASCO Annual Meeting. 
  • Chehrazi-Raffle A, Salgia N, Hsu J, Zengin ZB, Salgia S, Chawla N, Malhotra J, Dizman N, Muddasani R, Meza LA, Cianfrocca ME, Gong J, Anand S, Chiu VY, Yeh JJ, Pal SK. (2021, June 4). Bridging the gaps between tertiary and community care networks: Results from a Southern California survey research analysis. Poster presented by A Chehrazi-Raffle at the 2021 ASCO Annual Meeting. 
  • Zengin ZB, Malhotra J, Salgia SK, Yost S, Chawla N, Govindarajan A, Hsu J, Salgia N, Bergerot PG, Meza L, Chehrazi-Raffle A, Muddasani R, Gillece J, Yuan Y, Highlander S, Pal SK. (2021, September 5). Associations between sarcopenia and gut microbiota in patients (pts) with metastatic renal cell carcinoma (mRCC) and breat cancer (BC). Oral abstract presented by Z Zengin at the 2021 ESMO Congress. 
  • Salgia SK, Malhotra J, Zengin Z, Meza L, Ely J, Hsu J, Kelley E, Chehrazi-Raffle A, Govindarajan A, Muddasani R, Salgia N, Dizman N, Chawla N, Dorff T, Lyou Y, Karczewska E, Trent J, Salgia R, Altin J, Pal SK. (2021, September 5). Characterization of COVID-19 vaccination response by antibody (Ab) titer and T-cell receptor (TCR) sequencing in patients with advanced genitourinary (GU) cancers. Oral abstract presented by S Salgia at the 2021 ESMO Congress.
  • Dizman N, Meza LA, Bergerot PG, Dorff TB, Lyou Y, Frankel PH, Mira V, Llamas M, Hsu J, Zengin ZB, Salgia N, Salgia S, Malhotra J, Chawla NS, Chehrazi-Raffle A, Gillece JD, Reining LJ, Trent JM, Takahashi M, Oka K, Higashi S, Highlander SK, Pal SK. (2021, October 8). Nivolumab/ipilimumab with or without CBM588 in metastatic renal cell carcinoma: a randomized phase Ib study and in-depth analysis of gut microbiome evolution. Oral abstract presented by N Dizmann at the 2021 Kidney Cancer Research Summit. 
  • Salgia NJ, Li H, Mambetsariev I, Dizman N, Zengin Z, Mirzapoiazova T, Zhao D, Kulkarnin P, Pal SK. (2021, October 8). Multiplex analysif of the tumor microenvironment in papillary renal cell carcinoma (pRCC) suggests a role of macrophages in therapeutic response. Oral abstract presented at the 2021 Kidney Cancer Research Summit.
  • Salgia NJ, Pal SK, Chung V, Tagawa ST, Picus J, Babiker HM, Wadlow RC, Poore J, Peterson C, Benaim E. "Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial carcinoma: preliminary results from a phase IIa study." American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium. February 14-16, 2019. 
  • Salgia NJ, Hansen BJ, Hoummse M, Iancau A, Mosheim A, Li N, Kahali O, Afzal M, Hummel JD, Fedorov VV. "Impact of adenosine on reentrant driver characteristics revealed by multi-electrode mapping in atrial fibrillation patients." Denman Undergraduate Research Forum at The Ohio State University. February 20, 2019.
  • Bergerot PG, Bergerot CD, Dizman N, Salgia N, Hsu J, Pal SK. "Efficacy of systemic treatment for metastatic renal cell carcinoma (mRCC) guided by comprehensive genomic profiling (CGP)." ASCO Quality Care Symposium. September 6-7, 2019. 
  • Salgia NJ. "Overview of renal cell carcinoma: presentation, treatment, and outcomes." TGen-City of Hope Microbiome Retreat. September 30-October 1, 2019. 
  • Bergerot CD, Bergerot PG, Philip EJ, Salgia M, Salgia NJ, Dizman N, Hsu J, Pal SK. "Genomic profiling: shared decision-making and emotional well-being among patients with metastatic genitourinary cancers." ASCO Supportive Care in Oncology Symposium. October 24-25, 2019. 
  • Salgia N, Dizman N, Bergerot PG, Bergerot CD, Hsu J, Pal SK. "Progression-free survival and overall survival across ethnicities for patients receiving first-line targeted therapies for the treatment of metastatic renal cell carcinoma." city of Hope Comprehensive Cancer Center Poster Day. October 29, 2019. 
  • Salgia N, Pal SK, Aix SP, Loriot Y, Dreicer R, Vaishampayan U, Choueiri TK, Schoffski P, Curran D, Liu Y, Lim FL, Neal J, Agarwal n. "Expansion cohorts of non-small cell lung cancer (NSCLC) and castration resistant prostate cancer (CRPC) in COSMIC-021, a phase 1b study of cabozantinib plus atezolizumab." Society for Immunotherapy for Cancer (SITC) Annual Meeting. November 6-10, 2019. 
  • Salgia NJ, Feng M, Prajapati D, Harwood R, Nissanoff M, Dara Y, Ruel N, Salgia M, Pal SK. "Association of academic rank and productivity with metrics of Twitter utilization amongst kidney cancer experts." 18th Annual International Kidney Cancer Symposium. November 15-16, 2019. 
  • Dizman N, Bergerot PG, Bergerot CD, Philip EJ, Salgia NJ, Hsu J, Pal SK. "Association of clinical benefit from first-line treatment and clinical benefit in further lines or overall survival in metastatic renal cell carcinoma." 18th Annual International Kidney Cancer Symposium. November 15-16, 2019. 
  • Bergerot CD, Philip EJ, Bergerot PG, Hsu J, Dizman N, Salgia M, Salgia N, Vaishampayan U, Battle D, Loscalzo M, Dale W, Pal SK. Perspective matters: patient vs. physician reported ECOG performance status. 18th Annual International Kidney Cancer Symposium. November 15-16, 2019. 
  • Hansen B, Helfrich KM, Zhal J, Li N, Salgia N, Houmsse MM, Iancau A, Zolotarev A, Dylov D, Zakharkin S, Kalyanasundaram A, Artiga E, Kahaly O, Janssen P, Mohler P, Mokadam N, Whitson B, Afzal MR, Simonetti O, Hummel J, Fedorov VV. "Unmasking hidden hubs of reentry driving persistent atrial fibrillation through challenge of driver physiology." American Heart Association Scientific Sessions. November 16-18, 2019. 
  • Salgia N, Dizman N, Bergerot PG, Bergerot CD, Hsu J, Pal SK. "Progression-free survival and overall survival across ethnicities for patients with metastatic renal cell carcinoma receiving targeted therapies as first-line treatment." ASCO Genitourinary Cancers Symposium. February 13-15, 2020. 
  • Philip EJ, Bergerot CD, Bergerot P, Salgia M, Salgia N, Dizman N, Hsu J, Pal SK. "Exploring motivation to pursue genomic profiling among patients with metastatic genitourinary cancers." ASCO Genitourinary Cancers Symposium. February 13-15, 2020. 
  • Bergerot CD, Philip E, Bergerot PG, Salgia N, Salgia M, Hsu J, Dizman N, Pal SK. "Prognostic understanding in advanced genitourinary cancer and its association with clinical characteristics." ASCO Genitourinary Cancers Symposium. February 13-15, 2020. 
  • Salgia NJ, Dizman N, Lyou Y, Bergerot PG, Hsu J, Byron SA, Trent JM, Pal SK. "Genomic and transcriptomic correlates of clinical benefit from immunotherapy and targeted therapy among patients with metastatic renal cell carcinoma." ASCO Annual Meeting. May 29-31, 2020.
  • Zengin ZB, Dizman N, Salgia NJ, Jones JO, Zhang J, Liu Y, Xu B, Li F, Wang Y, Li M, Du R, Zhou Y, Hsu J, Salgia M, Yang L, Pal SK. "Circulating tumor DNA sequencing analysis of patients with metastatic renal cell carcinoma." ASCO Annual Meeting. May 29-31, 2020. 
  • Salgia N, Dizman N, Mambetsariev I, Mirzapoiazova T, Zhao D, Kulkarni P, Salgia R, Pal SK. "Genomic and immunohistochemical characterization of patients with advanced papillary renal cell carcinoma: focus on exceptional responders." American Association of Cancer Research (AACR) Annual Meeting. June 22-24, 2020.
  • Zengin ZB, Weipert C, Hsu J, Salgia NJ, Nagy R, Agarwal N, Pal SK. "Circulating tumor DNA (ctDNA) and tissue genomic analysis in metastatic renal cell carcinoma." European Society of Medical Oncology (ESMO) Annual Congress. September 19-21, 2020. 
  • Bergerot CD, Philip E, Salgia N, Bergerot PG, Hsu J, Dizman N, Dale W, Pal SK. "Comparing the relationship of perceptions of immunotherapy with anxiety between older and younger patients with advanced genitourinary cancer." ASCO Quality Care Symposium. October 9-10, 2020. 
  • Dandapani S, Salgia N, Dizman N, Zengin N, Hsu J, Pal SK. "Efficacy and toxicity of radiotherapy for oligoprogression of metastatic renal cell carcinoma". American Society for Radiation Oncology (ASTRO) Annual Meeting. October 24-28, 2020. 
  • Dizman N, Hsu J, Salgia N, Zengin Z, Chawla N, Meza L, Salgia S, Malhotra J, Pal, SK. "Preclinical development of a novel colon-targeted therapeutic for the treatment of immune checkpoint inhibitor-colitis." SITC Annual Meeting. November 10-15, 2020.